Voronoi Files Phase 1 IND Application for Non-Small Cell Lung Cancer Therapy VRN11
2023.06.28
⚫ Efficacy against EGFR C797S expected... Clinical trial to be conducted at some 10 sites in Korea, the U.S., and Taiwan
Voronoi, a precision targeted therapy drug design company, disclosed on the 28th that it has submitted an IND application (clinical trial authorization application) for VRN11, its non-small cell lung cancer (NSCLC) therapy, to the Ministry of Food and Drug Safety (MFDS).
Voronoi disclosed on the same day that it has applied for authorization of a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of VRN11 in patients with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer. The Phase 1 clinical trial of VRN11 will be conducted in approximately 50 non-small cell lung cancer patients at some 10 sites in Korea, the U.S., and Taiwan. In addition to safety, including adverse events in patients, the Phase 1 trial will also evaluate efficacy endpoints such as objective response rate (ORR), progression-free survival (PFS), and intracranial response rate. This trial will allow confirmation of the therapeutic effect of VRN11 in patients with EGFR C797S mutation non-small cell lung cancer, which arises from resistance to existing drug therapies for EGFR mutation non-small cell lung cancer.
In particular, VRN11 demonstrated 100% brain penetrance (Kp,uu,brain) in preclinical studies, and is therefore expected to be effective in treating brain metastases, from which about half of EGFR non-small cell lung cancer patients suffer.
Daekwon Kim, CEO of the Research Division of Voronoi, said, "VRN11 has potent activity not only against EGFR C797S but also against primary cancer mutations (Del19, L858R, and uncommon mutations), so we expect to expand its indications. We hope that the clinical success of VRN11 will free EGFR mutation non-small cell lung cancer patients from their suffering as soon as possible."
Voronoi plans to present VRN11's preclinical data at the World Conference on Lung Cancer (IASLC WCLC 2023) in the second half of the year.
In addition to medicinal synthesis and cell-based experiments, Voronoi has its own animal research center and artificial intelligence (AI) research institute, which is rare in Korea. By producing 550,000 experimental data points per year and feeding them back into its AI, the company continuously advances its R&D platform, deriving compounds with outstanding competitiveness in 'selectivity,' binding only to the disease-causing target protein, and 'BBB penetration,' the drug's ability to cross the blood-brain barrier.
On this basis, Voronoi has built up cumulative commercialization achievements of approximately USD 2.3 billion (approximately KRW 3 trillion) through five global license-out deals since 2020.
Voronoi, a precision targeted therapy drug design company, disclosed on the 28th that it has submitted an IND application (clinical trial authorization application) for VRN11, its non-small cell lung cancer (NSCLC) therapy, to the Ministry of Food and Drug Safety (MFDS).
Voronoi disclosed on the same day that it has applied for authorization of a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of VRN11 in patients with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer. The Phase 1 clinical trial of VRN11 will be conducted in approximately 50 non-small cell lung cancer patients at some 10 sites in Korea, the U.S., and Taiwan. In addition to safety, including adverse events in patients, the Phase 1 trial will also evaluate efficacy endpoints such as objective response rate (ORR), progression-free survival (PFS), and intracranial response rate. This trial will allow confirmation of the therapeutic effect of VRN11 in patients with EGFR C797S mutation non-small cell lung cancer, which arises from resistance to existing drug therapies for EGFR mutation non-small cell lung cancer.
In particular, VRN11 demonstrated 100% brain penetrance (Kp,uu,brain) in preclinical studies, and is therefore expected to be effective in treating brain metastases, from which about half of EGFR non-small cell lung cancer patients suffer.
Daekwon Kim, CEO of the Research Division of Voronoi, said, "VRN11 has potent activity not only against EGFR C797S but also against primary cancer mutations (Del19, L858R, and uncommon mutations), so we expect to expand its indications. We hope that the clinical success of VRN11 will free EGFR mutation non-small cell lung cancer patients from their suffering as soon as possible."
Voronoi plans to present VRN11's preclinical data at the World Conference on Lung Cancer (IASLC WCLC 2023) in the second half of the year.
In addition to medicinal synthesis and cell-based experiments, Voronoi has its own animal research center and artificial intelligence (AI) research institute, which is rare in Korea. By producing 550,000 experimental data points per year and feeding them back into its AI, the company continuously advances its R&D platform, deriving compounds with outstanding competitiveness in 'selectivity,' binding only to the disease-causing target protein, and 'BBB penetration,' the drug's ability to cross the blood-brain barrier.
On this basis, Voronoi has built up cumulative commercialization achievements of approximately USD 2.3 billion (approximately KRW 3 trillion) through five global license-out deals since 2020.